• Anthera Pharmaceuticals Inc., of Hayward, Calif., said it initiated the BRIGHT-SC Phase II study of blisibimod, an inhibitor of B-cell activating factor (BAFF), for the treatment of IgA nephropathy, a chronic autoimmune renal disease characterized by proteinuria and progression to end-stage renal disease.